Travere Therapeutics Announces Late-Breaking Data From Phase 3 Studies Of Sparsentan In IgAN And FSGS Published In The Lancet And The NEJM Respectively And Presented At The American Society Of Nephrology Kidney Week 2023
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics has announced late-breaking data from Phase 3 studies of Sparsentan in IgAN and FSGS. The results suggest that Sparsentan has the potential to preserve kidney function and significantly delay time to kidney failure. The drug was well tolerated with a safety profile comparable to the maximally tolerated dose of irbesartan in both Phase 3 studies.
November 03, 2023 | 2:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Travere Therapeutics' Phase 3 studies of Sparsentan show promising results, potentially leading to increased investor confidence and positive impact on the company's stock.
The positive results from the Phase 3 studies of Sparsentan suggest that the drug has the potential to preserve kidney function and delay kidney failure. This could lead to increased demand for the drug, potentially boosting Travere Therapeutics' revenues and positively impacting the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100